MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale.
The company focuses on developing antibody-derived treatments for inflammatory skin conditions.
The is in preliminary talks with pharmaceutical companies interested in a potential acquisition. Citing the sources, Reuters emphasized that a deal isn’t guaranteed and wished to remain anonymous.
Companies specializing in immunology have been popular acquisition targets, as indicated by recent acquisitions such as Merck & Co Inc’s (NYSE: MRK) purchase of Prometheus BioSciences …
